Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6006 mRNA Vaccine Booster in Inactivated Vaccine Recipients
NCT05492643Unknown
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Aug 2022
- Primary completion
- Feb 2023
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Open-label trial of SYS6006 in coronavirus disease 2019 (COVID-19), sponsored by Zhongnan Hospital of Wuhan University. Primary endpoint: Primary Safety Endpoint at 6 months. Status: unknown.
02
Drugs
SYS6006
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05492643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05492643.